ArticlePloS one2017
Edaravone protects against hyperosmolarity-induced oxidative stress and apoptosis in primary human corneal epithelial cells.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 54 citations in OpenAlex.
- Pathological mechanisms of Sjögren's disease-related dry eye: from multiglandular dysfunction to ocular surface inflammation.International ophthalmology · 2026Review
- Altered Carnitine Homeostasis Modulates Hyperosmolarity-Induced Mitochondrial Dysfunction and Lipotoxicity in Human Corneal Epithelial Cells.Investigative ophthalmology & visual science · 2026Article
- Multifaceted mitochondrial as a novel therapeutic target in dry eye: insights and interventions.Cell death discovery · 2024Review
- Options for Topical Treatment of Oxidative Eye Diseases with a Special Focus on Retinopathies.Medicina (Kaunas, Lithuania) · 2024Review
- Modeling drug-induced mitochondrial toxicity with human primary cardiomyocytes.Science China. Life sciences · 2024Article
- Mitochondrial Chronic Progressive External Ophthalmoplegia.Brain sciences · 2024Review
- Targeting Nrf2 signaling in dry eye.International journal of ophthalmology · 2024Review
- The Potential Role of Regulated Cell Death in Dry Eye Diseases and Ocular Surface Dysfunction.International journal of molecular sciences · 2023Review
- Exogenous Melatonin Ameliorates the Negative Effect of Osmotic Stress in Human and Bovine Ovarian Stromal Cells.Antioxidants (Basel, Switzerland) · 2022Article
- Hyperosmolality in CHO cell culture: effects on the proteome.Applied microbiology and biotechnology · 2022Article
- Edaravone attenuates disease severity of experimental auto-immune encephalomyelitis and increases gene expression of Nrf2 and HO-1.Physiological research · 2022Article
- Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection.Antioxidants (Basel, Switzerland) · 2022Review
- Edaravone Attenuated Particulate Matter-Induced Lung Inflammation by Inhibiting ROS-NF-Oxidative medicine and cellular longevity · 2022Article
- Glucose-impaired Corneal Re-epithelialization Is Promoted by a Novel Derivate of Dimethyl Fumarate.Antioxidants (Basel, Switzerland) · 2021Article
- Edaravone attenuates smoke inhalation injury in rats by the Notch pathway.American journal of translational research · 2021Article
- Demystifying Oxidative Stress.Handbook of experimental pharmacology · 2021Article
- Autophagy Activation Protects Ocular Surface from Inflammation in a Dry Eye Model In Vitro.International journal of molecular sciences · 2020Article
- Effects ofExperimental and therapeutic medicine · 2020Article
- Protective effect of high-affinity liposomes encapsulating astaxanthin against corneal disorder in theJournal of clinical biochemistry and nutrition · 2020Article
- Acupoint selection for the treatment of dry eye: A systematic review and meta-analysis of randomized controlled trials.Experimental and therapeutic medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An increase in the osmolarity of tears induced by excessive evaporation of the aqueous tear phase is a major pathological mechanism behind dry eye. Exposure of epithelial cells on the surface of the human eye to hyperosmolarity leads to oxidative stress, mitochondrial dysfunction, and apoptosis. Edaravone, a hydroxyl radical scavenging agent, is clinically used to reduce neuronal damage following ischemic stroke. In this study, we found that treatment with hyperosmotic media at 400 and 450 mOsM increased the levels of ROS and mitochondrial oxidative damage, which were ameliorated by edaravone treatment in a dose-dependent manner. We also found that edaravone could improve mitochondrial function in HCEpiCs by increasing the levels of ATP and mitochondrial membrane potential. MTT and LDH assays indicated that edaravone could attenuate hyperosmolarity-induced cell death. It was found that edaravone prevented apoptosis by decreasing the level of cleaved caspase-3, and attenuating the release of cytochrome C. Mechanistically, we found that edaravone augmented the expression of Nrf2 and its target genes, such as HO-1, GPx-1, and GCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.